BridgeBio Pharma, Inc. $BBIO Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 3.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 93,120 shares of the company’s stock after purchasing an additional 3,126 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in BridgeBio Pharma were worth $3,224,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BBIO. Frazier Life Sciences Management L.P. lifted its holdings in BridgeBio Pharma by 1.1% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock worth $104,285,000 after buying an additional 40,000 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of BridgeBio Pharma by 132.9% in the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company’s stock valued at $60,684,000 after purchasing an additional 1,261,772 shares during the last quarter. Invesco Ltd. increased its position in BridgeBio Pharma by 147.0% in the 1st quarter. Invesco Ltd. now owns 2,206,163 shares of the company’s stock valued at $76,267,000 after acquiring an additional 1,313,036 shares during the period. Cormorant Asset Management LP increased its position in BridgeBio Pharma by 25.0% in the 1st quarter. Cormorant Asset Management LP now owns 2,000,000 shares of the company’s stock valued at $69,140,000 after acquiring an additional 400,000 shares during the period. Finally, Driehaus Capital Management LLC purchased a new position in shares of BridgeBio Pharma during the 1st quarter worth approximately $51,874,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other BridgeBio Pharma news, CFO Thomas Trimarchi sold 42,237 shares of BridgeBio Pharma stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $49.48, for a total transaction of $2,089,886.76. Following the completion of the sale, the chief financial officer owned 421,081 shares of the company’s stock, valued at approximately $20,835,087.88. The trade was a 9.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Maricel Apuli sold 1,000 shares of the business’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $45.44, for a total transaction of $45,440.00. Following the completion of the sale, the chief accounting officer directly owned 141,859 shares in the company, valued at $6,446,072.96. This represents a 0.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,202,620 shares of company stock worth $187,174,970. Corporate insiders own 18.20% of the company’s stock.

BridgeBio Pharma Price Performance

BridgeBio Pharma stock opened at $51.21 on Friday. BridgeBio Pharma, Inc. has a one year low of $21.72 and a one year high of $54.60. The company’s fifty day moving average price is $48.54 and its two-hundred day moving average price is $40.27. The company has a market capitalization of $9.79 billion, a price-to-earnings ratio of -12.52 and a beta of 1.25.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Tuesday, August 5th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $110.57 million for the quarter, compared to analyst estimates of $98.46 million. The business’s revenue for the quarter was up 4999.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.39) EPS. As a group, sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wolfe Research started coverage on BridgeBio Pharma in a research report on Tuesday, June 17th. They set an “outperform” rating and a $49.00 price target for the company. Wells Fargo & Company boosted their price target on BridgeBio Pharma from $67.00 to $76.00 and gave the stock an “overweight” rating in a research note on Monday, June 30th. UBS Group increased their price target on BridgeBio Pharma from $72.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday. Cantor Fitzgerald reissued an “overweight” rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a report on Tuesday, July 29th. Finally, Oppenheimer upped their target price on BridgeBio Pharma from $60.00 to $61.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 6th. Seventeen research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $63.94.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.